title: Duration of the effect of intravitreal triamcinolone acetonide as treatment for diffuse diabetic macular edema.
abstract: OBJECTIVE
  To evaluate the duration of the effect of intravitreal triamcinolone acetonide on visual acuity in patients with diffuse diabetic macular edema.
  
  
  METHODS
  Clinical interventional case series.
  
  
  METHODS
  Subjects were 31 patients (38 eyes) with diffuse diabetic macular edema who received an intravitreal injection of 20- to 25-mg triamcinolone acetonide. Mean follow-up time was 13.2 +/- 6.0 months (6.03-25.2 months).
  
  
  RESULTS
  Visual acuity and intraocular pressure began to increase significantly (P =.003) within the first week, reaching a plateaulike maximum at 1 to 7 months postinjection, returning to baseline values 8 to 9 months postinjection.
  
  
  CONCLUSIONS
  The effect of an intravitreal injection of approximately 20- to 25-mg triamcinolone acetonide in patients with diffuse diabetic macular edema lasts approximately 7 to 8 months. This information may be helpful in determining the optimal dosage of intravitreal triamcinolone acetonide for the treatment of diffuse diabetic macular edema.
authors.affiliation: Department of Ophthalmology, Faculty of Clinical Medicine Mannheim, University of Heidelberg, Heidelberg, Germany. Jost.Jonas@ma.augen.uni-heidelberg.de
authors.forename: Jost B
authors.initials: JB
authors.lastname: Jonas
authors.forename: Robert F
authors.initials: RF
authors.lastname: Degenring
authors.forename: Bernd A
authors.initials: BA
authors.lastname: Kamppeter
authors.forename: Ingrid
authors.initials: I
authors.lastname: Kreissig
authors.forename: Imren
authors.initials: I
authors.lastname: Akkoyun
mesh_terms: D000368:Aged; D003930:Diabetic Retinopathy / Q000188:drug therapy*; D005451:Fluorescein Angiography; D005938:Glucocorticoids / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D007267:Injections; D007429:Intraocular Pressure / Q000187:drug effects; D008269:Macular Edema / Q000188:drug therapy*; D013997:Time Factors; D041623:Tomography, Optical Coherence; D014222:Triamcinolone Acetonide / Q000008:administration & dosage* / Q000627:therapeutic use; D014792:Visual Acuity / Q000187:drug effects; D014822:Vitreous Body
chemical_list: D005938:Glucocorticoids; D014222:Triamcinolone Acetonide